Gregory Piazza Presents HI-PRO Trial Results on VTE at ESC Congress
Gregory Piazza, Director of the Vascular Medicine Section at Brigham and Women’s Hospital, posted on LinkedIn:
‘‘Venous thromboembolism (VTE) has traditionally been categorized as unprovoked and treated with extended anticoagulation or provoked and prescribed time-limited anticoagulation for 3 months.
What do we do with patients who have provoked events but other persistent risk factors like obesity or heart disease?
We answered this question in the HI-PRO randomized controlled trial presented in Madrid at the European Society of Cardiology Congress and simultaneously published in the New England Journal of Medicine.
The culmination of 5 years of blood, sweat, and almost tears, it would not have been possible without an amazing team, my co-investigators and the Thrombosis Research Group team!”
Watch the full video here.
Read the full article in NEJM.
Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism
Authors: Gregory Piazza, Behnood Bikdeli, Arvind Pandey, Darsiya Krishnathasan, Candrika Khairani, Antoine Bejjani, Ruth Morrison, Heather Hogan, Sina Rashedi, Mariana Pfeferman, Junyang Lou, John Fanikos, Nicole Porio, Lisa Rosenbaum, Piotr Sobieszczyk, Zhou Lan, Marie Gerhard-Herman, Umberto Campia, Samuel Goldhaber
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Nov 2, 2025, 14:172019 ESC/EAS Guidelines for the Management of Dyslipidaemias Discussion with Lale Tokgözoğlu and Jeanine Roeters van Lennep
-
Nov 2, 2025, 14:14Nihar Desai: Post-Transplant Dysphagia
-
Nov 2, 2025, 14:13Zia Choudhry Launchs a New Digital Education Platform Designed to Inform and Empower People Living With wAIHA
-
Nov 2, 2025, 14:13Rahul Bhargava: Landmark Study Shows Excellent Outcomes in Pediatric AML Transplant
-
Nov 2, 2025, 10:17ESO: Register for the Live WSC 2025 Highlights Webinar
-
Nov 2, 2025, 14:21Claude Franceschi: I Advise You to Understand the Hemodynamic Pathophysiology of Venous Diseases Rather than Blindly Applying Ablation Techniques or Venous Stent Placement
-
Nov 2, 2025, 14:15Krishna Aragam: Why are (DCM) and Heart Failure About Twice as Common in Individuals of Self-Identified Black Race?
-
Nov 2, 2025, 14:15Raul Santos: Waist-to-Height Ratio and Coronary Artery Calcium Incidence
-
Nov 2, 2025, 14:12Steven AR Murphy: Urolithin A Shows Immune Rejuvenation and Mitochondrial Benefits in New Trial
-
Nov 2, 2025, 10:31Cihan Ay and RIETE Investigators Team Present External Validation of the VTE-PREDICT Score
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Oct 28, 2025, 06:49Lukas Gaats: Researchers Are Building Reproductive Organoids
-
Nov 2, 2025, 14:17Anamaria B: Your Mother Still Runs Part of Your DNA
-
Nov 2, 2025, 10:57Paul Bolaji on Launching The First Centralised Nigerian National Stroke Registry
-
Nov 2, 2025, 10:03Mark Stoffels: A Stroke Can Change Lives in an Instant, But With Timely Expert Care Recovery is Possible
-
Nov 2, 2025, 09:43Louise Bannon Celebrates Barbara Adams Krolak’s 10-Year Anniversary at ISTH
-
Nov 2, 2025, 08:06Sanam Loghavi Recognized at Inaugural Women in Hematology U.S. Focus Meeting 2025